Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa

被引:198
作者
Barnes, KI [1 ]
Durrheim, DN
Little, F
Jackson, A
Mehta, U
Allen, E
Dlamini, SS
Tsoka, J
Bredenkamp, B
Mthembu, DJ
White, NJ
Sharp, BL
机构
[1] Univ Cape Town, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa
[2] Hunter New England Populat Hlth, Hlth Protect, Newcastle, NSW, Australia
[3] Univ Cape Town, Dept Stat Sci, ZA-7925 Cape Town, South Africa
[4] MRC, Malaria Lead Res Programme, Durban, South Africa
[5] Mahidol Univ, Fac Trop Med, Bangkok 10700, Thailand
[6] Churchill Hosp, Ctr Vaccinol & Trop Med, Oxford OX3 7LJ, England
基金
英国惠康基金;
关键词
D O I
10.1371/journal.pmed.0020330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Between 1995 and 2000, KwaZulu-Natal province, South Africa, experienced a marked increase in Plasmodium falciparum malaria, fuelled by pyrethroid and sulfadoxine-pyrimethamine resistance. In response, vector control was strengthened and artemether-lumefantrine (AL) was deployed in the first Ministry of Health artemisinin-based combination treatment policy in Africa. In South Africa, effective vector and parasite control had historically ensured low-intensity malaria transmission. Malaria is diagnosed definitively and treatment is provided free of charge in reasonably accessible public-sector health-care facilities. Methods and Findings We reviewed four years of malaria morbidity and mortality data at four sentinel health-care facilities within KwaZulu-Natal's malaria-endemic area. In the year following improved vector control and implementation of AL treatment, malaria-related admissions and deaths both declined by 89%, and outpatient visits decreased by 85% at the sentinel facilities. By 2003, malaria-related outpatient cases and admissions had fallen by 99%, and malaria-related deaths had decreased by 97%. There was a concomitant marked and sustained decline in notified malaria throughout the province. No serious adverse events were associated causally with AL treatment in an active sentinel pharmacovigilance survey. In a prospective study with 42 d follow up, AL cured 97/98 (99%) and prevented gametocyte developing in all patients. Consistent with the findings of focus group discussions, a household survey found self-reported adherence to the six-dose AL regimen was 96%. Conclusion Together with concurrent strengthening of vector control measures, the antimalarial treatment policy change to AL in KwaZulu-Natal contributed to a marked and sustained decrease in malaria cases, admissions, and deaths, by greatly improving clinical and parasitological cure rates and reducing gametocyte carriage.
引用
收藏
页码:1123 / 1134
页数:12
相关论文
共 49 条
[1]  
Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8
[2]   Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children:: a randomised, multicentre trial [J].
Adjuik, M ;
Agnamey, P ;
Babiker, A ;
Borrmann, S ;
Brasseur, P ;
Cisse, M ;
Cobelens, F ;
Diallo, S ;
Faucher, JF ;
Garner, P ;
Gikunda, S ;
Kremsner, PG ;
Krishna, S ;
Lell, B ;
Loolpapit, M ;
Matsiegui, PB ;
Missinou, MA ;
Mwanza, J ;
Ntoumi, F ;
Olliaro, P ;
Osimbo, P ;
Rezbach, P ;
Some, E ;
Taylor, WRJ .
LANCET, 2002, 359 (9315) :1365-1372
[3]  
Baker L, 2001, S AFR MED J, V91, P358
[4]  
Bloland PB, 2000, B WORLD HEALTH ORGAN, V78, P1378
[5]   A contrarian view of malaria therapy policy in Africa [J].
Bloland, PB .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 68 (02) :125-126
[6]  
Bredenkamp BLF, 2001, SAMJ S AFR MED J, V91, P970
[7]   Exploring 30 years of malaria case data in KwaZulu-Natal, South Africa: Part II. The impact of non-climatic factors [J].
Craig, MH ;
Kleinschmidt, I ;
Le Sueur, D ;
Sharp, BL .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2004, 9 (12) :1258-1266
[8]  
Craig MH, 2004, TROP MED INT HEALTH, V9, P1247, DOI 10.1111/j.1365-3156.2004.01340.x
[9]   Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial [J].
Dorsey, G ;
Njama, D ;
Kamya, MR ;
Cattamanchi, A ;
Kyabayinze, D ;
Staedke, SG ;
Gasasira, A ;
Rosenthal, PJ .
LANCET, 2002, 360 (9350) :2031-2038
[10]   Drug combinations for malaria: time to ACT? [J].
Duffy, PE ;
Mutabingwa, TK .
LANCET, 2004, 363 (9402) :3-4